Clinicopathologic factors associated with the development of sunitinib-induced hypertension (HTN) in patients (pts) with metastatic renal cell carcinoma (mRCC)

被引：0
|
作者：
Neiman, Victoria
Gottfried, Maya
Hammers, Hans J.
Eisenberger, Mario A.
Carducci, Michael Anthony
Sinibaldi, Victoria J.
Rosenbaum, Eli
Sarid, David
Gez, Eliahu
Peer, Avivit
Neumann, Avivit
Kovel, Svetlana
Selia, Avishay
Mermershtain, Wilmesh
Rouvinov, Keren
Berger, Raanan
Keizman, Daniel
机构：
[1] Rabin Med Ctr, Davidoff Canc Ctr, Petah Tiqwa, Israel
[2] Meir Med Ctr, Lung Canc Unit, Kefar Sava, Israel
[3] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[4] Rabin Med Ctr, Dept Oncol, Petah Tiqwa, Israel
[5] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Div Oncol, IL-69978 Tel Aviv, Israel
[6] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel
[7] Rambam Hlth Care Campus, Haifa, Israel
[8] Rambam Med Ctr, Dept Oncol, Haifa, Israel
[9] Asaf Harofe Med Ctr, Dept Oncol, Zerifin, Israel
[10] Assaf Harofeh Med Ctr, IL-70300 Zerifin, Israel
[11] Soroka Med Ctr, Beer Sheva, Israel
[12] Meir Med Ctr, Dept Oncol, Kefar Sava, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.e15551
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15551
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Hypertension and cardiotoxicity in metastatic renal cell carcinoma (mRCC) treated with sunitinib (SU)
    Prati, Veronica
    Ortega, Cinzia
    Ballatore, Valentina
    Galizia, Danilo
    Ruatta, Fiorella
    Bonzano, Alessandro
    Aliberti, Sandra
    Grignani, Giovanni
    Aglietta, Massimo
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] Influence of risk factors for renal cell carcinoma (RCC) on outcome of patients (pts) with metastatic disease (mRCC) treated with sunitinib (Su)
    Berger, Raanan
    Keizman, Daniel
    Ish-Shalom, Maya
    Hammers, Hans J.
    Eisenberger, Mario A.
    Sinibaldi, Victoria J.
    Pili, Roberto
    Boursi, Ben
    Maimon, Natalie
    Gottfried, Maya
    Hayat, Henry
    Peer, Avivit
    Kovel, Svetlana
    Sella, Avishay
    Carducci, Michael Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [23] Sunitinib safety and tolerability in patients with metastatic renal cell carcinoma (MRCC)
    Ferrari, A.
    Sabbatini, R.
    Maur, M.
    Giovannelli, S.
    Jovic, G.
    Conte, P.
    ANNALS OF ONCOLOGY, 2006, 17 : XI83 - XI83
  • [24] Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients
    Kim, Hye Ryun
    Park, Hyung Soon
    Kwon, Woo Sun
    Lee, Ji Hyun
    Tanigawara, Yusuke
    Lim, Sun Min
    Kim, Hyo Song
    Shin, Sang Jun
    Ahn, Jung Bae
    Rha, Sun Young
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (04) : 825 - 835
  • [25] Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients
    Hye Ryun Kim
    Hyung Soon Park
    Woo Sun Kwon
    Ji Hyun Lee
    Yusuke Tanigawara
    Sun Min Lim
    Hyo Song Kim
    Sang Jun Shin
    Jung Bae Ahn
    Sun Young Rha
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 825 - 835
  • [26] Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean patients with metastatic renal cell carcinoma
    Kim, Hye Ryun
    CANCER RESEARCH, 2012, 72
  • [27] Association of tumor burden characteristics with outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib
    Golshayan, A. R.
    Elson, P.
    Wood, L. S.
    Garcia, J. A.
    Dreicer, R.
    Rini, B. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] A phase II study of intermittent sunitinib in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC).
    Wood, Laura S.
    Dreicer, Robert
    Garcia, Jorge A.
    Gilligan, Timothy D.
    Ali, Khaled B.
    Haddad, Housam
    Shah, Shetal N.
    Elson, Paul
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [29] Immune cell changes in the peripheral blood of metastatic renal cell carcinoma (mRCC) patients (pts) treated with sunitinib or temsirolimus
    Salas, R. N.
    Ireland, J. L.
    Ko, J. S.
    Elson, P.
    Garcia, J. A.
    Wood, L.
    Bukowski, R. M.
    Rini, B. I.
    Finke, J. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [30] Phase 1/2 study of sunitinib in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Redman, B. G.
    Hudes, G. R.
    Kondagunta, G. V.
    Patel, P. H.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 302 - 302
12345